UPDATE: Piper Jaffray Raises Price Target on AtriCure to $14

by Benzinga Staff
February 28, 2012 10:40 AM | 19 seconds read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

According to Piper Jaffray, AtriCure (NASDAQ: ATRC) price target is raised to $14.Piper Jaffray said that AtriCure has been shackled by its lack of ability to market the company's key atrial fibrillation (AF) products for that indication. “We are upgrading to Overweight from Neutral and raising our PT to $14 from $11 based on improving earnings potential.”AtriCure closed yesterday at $10.35.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorPrice TargetAnalyst RatingsPiper Jaffray

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.